Recent SARS-CoV-2 seroconversion in a national, community-based prospective cohort of U.S. adults

Authors: Denis Nash[1,2*], Madhura Rane[1], Mindy Chang[1], Sarah Gorrell Kulkarni[1], Rebecca Zimba[1], William You[1], Amanda Berry[1], Chloe Mirzayi[1,2], Shivani Kochhar[1], Andrew Maroko[1,3], McKaylee M. Robertson[1], Drew Westmoreland[1], Angela Parcesepe[1,4,5], Levi Waldron[1,2], and Christian Grov[1,6]

Affiliations:

[1]Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); New York City, New York USA

[2]Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

[3]Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

[4]Department of Maternal and Child Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA

[5]Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

[6]Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

***CORRESPONDING AUTHOR:**
Denis Nash, Ph.D., MPH
City University of New York (CUNY) Graduate School of Public Health and Health Policy
55 W. 125th St., 6th Floor
New York, NY USA 10027
Email: denis.nash@sph.cuny.edu
Twitter: @epi_dude

SHORT ABSTRACT

Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via prospective cohort studies, complementing case-based surveillance and cross-sectional seroprevalence studies. In March 2020, we launched the CHASING COVID Cohort Study, a national, community-based prospective cohort study of 6,745 U.S. adults who underwent at-home specimen collection for repeat serologic testing for SARS-CoV-2 antibodies. We identify and quantify several policy-sensitive risk factors for recent SARS-CoV-2 seroconversion, highlight persistent racial/ethnic disparities in incidence, document continued elevated risk among essential workers, and call attention to major gaps in the coverage of public health interventions aimed at testing, isolation, and contact tracing. We conclude that modifiable risk factors and poor reach of public health strategies drive SARS-CoV-2 transmission and inequities across the U.S.

LONG ABSTRACT

Background

Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via prospective cohort studies, complementing case-based surveillance and cross-sectional seroprevalence studies.

Methods

We estimated the cumulative incidence of SARS-CoV-2 infection and incidence rates of seroconversion in a national prospective online cohort of 6,745 U.S. adults, enrolled March-July 2020. A subset (n=4,459) underwent serologic testing (Bio-Rad Platelia Total Ab, IgA/IgM/IgG), offered initially May-September 2020 and again November 2020-January 2021.

Results

A total of 303 of 4,459 individuals showed serologic evidence of past SARS-CoV-2 infection (cumulative incidence of 6.8%; 95% Confidence Interval [CI] 6.1%-7.6% [6.3%, 95% CI 5.7%-7.1% adjusting for laboratory test error]). Among 3,280 initially seronegative participants with a subsequent serologic test, we observed 145 seroconversions during 1,562 person years of follow-up (incidence rate of 9.3 per 100 person-years [95% CI 17.9-11.0]). Racial/ethnic disparities in crude incidence rates were apparent through January 2021 (rate ratio [$RR_{\text{Hispanic vs Whites}}$]=2.1; 95% CI 1.4-3.1; $RR_{\text{non-Hispanic Blacks vs Whites}}$=1.8; 95% CI 0.96-3.1). Incidence was higher in the southern ($RR_{\text{South vs Northeast}}$=1.7; 95% CI 1.1-2.8) and midwestern ($RR_{\text{Midwest vs Northeast}}$=1.6; 95% CI 0.98-2.7) regions, in rural vs urban areas (RR=1.5; 95% CI 1.0-2.2), and among essential workers (RR=1.7; 95% CI 1.1-2.5). Household crowding (RR=1.6, 95% CI 1.1-2.3), dining indoors at restaurants/bars (RR=2.0; 95% CI 1.4-2.8), visiting places of worship (RR=2.0; 95% CI 1.3-2.9), wearing masks sometimes vs always while grocery shopping (RR=2.5; 95% CI 1.3-4.4), indoor visits with people outside the household with masks ($RR_{\text{always mask vs no visit}}$=2.6; 95% CI 1.6-4.4) and without masks ($RR_{\text{sometimes mask vs no visit}}$=3.5; 95% CI 2.7-5.7; $RR_{\text{never mask vs no visit}}$=5.3; 95% CI 3.1-8.9); working indoors at a place of employment with masks ($RR_{\text{always mask vs no in-person}}$=2.0, 95% CI 1.4-2.8) and without masks ($RR_{\text{sometimes mask vs no in-person}}$= 2.0, 95% CI 1.1-

3.5; $RR_{never\ mask\ vs\ no\ in\text{-}person}$=3.7, 95% CI 1.3-8.5); attending a salon or gym with masks ($RR_{always\ mask\ vs\ no\ salon/gym}$=1.7 (95% CI 1.1-2.4), gathering indoors and outdoors in groups of ≥10 (RR=1.9, 95% CI 1.2-2.0); and air travel during the pandemic (RR=1.7; 95% CI 1.1-2.6) were also associated with higher incidence rates. Among 303 seropositive individuals, 27.4% had asymptomatic infection, and 32% reported a positive SARS-CoV-2 PCR test or provider diagnosis of COVID-19. In this group, there were major gaps in the coverage of public health interventions aimed at isolation (31% isolated) and contact tracing (asked about contacts [18%]; told about exposure to a confirmed case [7.6%]).

Conclusions

Modifiable risk factors and low reach of public health strategies drive SARS-CoV-2 transmission across the U.S. It is critical to address inequities in incidence, reduce risk factors, and improve the reach of public health strategies in the vaccine era.

KEYWORDS: COVID-19; serology, seroconversion, asymptomatic infection, physical distancing; natural history study, epidemiologic study, essential workers, public health interventions, community transmission

INTRODUCTION

As of this writing, about one year after the emergence of SARS-CoV-2 in the United States (U.S.), there have been more than 25 million SARS-CoV-2 cases diagnosed, 435,000 deaths recorded, and 23.5 million vaccine doses administered.[1] As compared to *diagnoses*, the true number of *infections* to date in the U.S. is unknown, but national estimates in the general population as measured by seroprevalence have put the cumulative incidence at 10% in September 2020[2] and 14% as of November 2020.[3] One recent study in a nationally representative sample of U.S. adults found that 4.6% had a history of undiagnosed SARS-CoV-2 as of July 2020: about 5 undiagnosed infections for every diagnosed case.[4]

A major challenge of controlling community transmission of SARS-CoV-2 is that the virus' infectious period allows for onward spread prior to recognition of infection, by the substantial proportion of people with asymptomatic infection, and during the pre-symptomatic period among those who go on to develop symptoms.[4,5]

While SARS-CoV-2 is understood to be transmitted from person-to-person via droplet and airborne spread, to date, the incidence of SARS-CoV-2 infection and risk factors for incident infection have not been well-characterized by routine case-based surveillance of SARS-CoV-2 diagnoses or by cross-sectional seroprevalence studies.[1–3] As the pandemic progresses through different seasons and stages, it is critical to continue to characterize COVID-19's evolving epidemiology and risk factors for SARS-CoV-2 acquisition, the uptake and impact of non-pharmaceutical interventions (NPIs)[6], and the reach of public health strategies aimed at controlling community transmission, including testing, quarantine, isolation, contact tracing, and vaccination.

Researchers and public health practitioners have called for prospective cohort studies to describe incidence rates and how they are influenced by NPI implementation and uptake, sociodemographics, knowledge and behaviors, and other potential risk factors.[7] Yet, both the frequency with which many risk factors occur in community samples, as well as the SARS-CoV-2 risk that could be attached to them, still have not been systematically assessed and epidemiologically linked to outcomes like seroconversion. Globally, few prospective epidemiologic studies of SARS-CoV-2 have been published to date. One recent global systematic review of observational studies of SARS-CoV-2 that employed serologic or PCR testing found 18 prospective studies.[8] Most were focused on healthcare workers or other

occupational groups, individuals in congregate settings, evacuees, or cruise ships; none were community-based (i.e., focused on risk factors in communities vs other higher risk populations/settings).[8] A greater understanding of SARS-CoV-2 incidence and risk factors in community samples can substantially complement routine case-based surveillance of new SARS-CoV-2 diagnoses and cross-sectional serosurveys, serving to inform aspects of implementation of the public health response and policies.

In late March 2020, we launched the national, prospective Communities, Households and SARS-CoV-2 Epidemiology (CHASING) COVID Cohort.[9] We describe the cumulative incidence of SARS-CoV-2 infection, risk factors for recent SARS-CoV-2 seroconversion, and, for those with serologic evidence of prior SARS-CoV-2 infection, the reach and uptake of public health strategies.

METHODS

We used internet-based strategies[10–12] to recruit a geographically and socio-demographically diverse cohort of adults in the U.S. and U.S. territories into longitudinal follow-up with at-home specimen collection. To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be aged 18 years or older; 3) provide a valid email address for follow-up; and 4) demonstrate early engagement in study activities (provided a baseline specimen or completed >1 recruitment/enrollment visits). Details of the study design and recruitment procedures have been described previously.[9]

Study measurements

Participant interviews. Measures included on the cohort screening, enrollment and follow-up questionnaires were derived from published research[10], BRFSS[13], 2009 H1N1 influenza studies[14,15], and other COVID-19 studies.[16] Measures were also developed *de novo*. Cohort recruitment and enrollment visits were completed between March 28-August 21, 2020, during which multiple rounds of interviews took place. Essential worker status was defined as working in law enforcement, emergency management, delivery, transportation, construction or healthcare at study enrollment. We separated healthcare workers from other essential workers and treated them as distinct categories in our analyses. From follow-up interviews we obtained repeated

measurements of symptoms, testing, hospitalizations, quarantine, isolation, contact tracing encounters, and other time-varying factors.

At-home specimen collection for serologic testing. As part of study assessments during May-August 2020 (Period 1) and November 2020-January 2021 (Period 2), participants were invited to participate in serologic testing using an at-home self-collected dried blood spot (DBS) specimen collection kit. Consenting participants were mailed a specimen collection kit, which included written instructions and a QR code for an instructional video. DBS cards were sent from and returned to the study laboratory (Molecular Testing Laboratories [MTL], Vancouver, Washington) via the U.S. Postal Service (self-addressed, stamped envelope containing a biohazard bag™).

Serologic testing. All DBS specimens were tested by the study laboratory for total antibodies (Total Ab) using the Bio-Rad Platelia test for IgA, IgM, and IgG which targets the SARS-CoV-2 nucleocapsid protein (manufacturer sensitivity 98.0%, specificity 99.3%).[17] Specimens that were reactive on the Total Ab test were tested further using the Euroimmun IgG test which targets the SARS-CoV-2 spike protein (manufacturer sensitivity 100%; specificity 99%).[17] Both assays received Emergency Use Authorization from the U.S. Food and Drug Administration and were further validated for use with DBS by the study laboratory using confirmed, true positive and negative patient specimens. In these local validations, both assays were found to have 100% sensitivity and 100% specificity (MTL, personal communication).

Cumulative incidence of SARS-CoV-2 infection. Among participants who underwent serologic testing, we estimated the cumulative incidence of SARS-CoV-2 as the proportion of individuals with a positive Total Ab test in either of the two time periods (i.e., number of participants ever-positive) divided by the total number of persons with one or more Total Ab tests (i.e., number of participants ever tested). We adjusted cumulative incidence estimates for laboratory test error as reported by the kit manufacturer. Crude cumulative incidence estimates are presented alongside adjusted estimates in supplemental tables. Unless otherwise specified, all cumulative incidence estimates presented are adjusted for laboratory test error using the following formula[18]:

$$Adjusted\ cumulative\ incidence = \frac{Crude\ cumulative\ incidence + Specificity - 1}{Sensitivity + Specificity - 1}$$

Observed SARS-CoV-2 seroconversion and seroreversion. Among those individuals with two Total Ab tests, an observed seroconversion was defined as a negative Total Ab test in Period 1 followed by a positive Total Ab test in Period 2. We estimated the rate of seroconversion per 100 person years of follow-up using the collection dates for each specimen. Person-time at risk began at the time of dried blood spot sample collection for the first serologic test or date the lab received the sample if collection date was missing. The seroconversion date was assigned as the midpoint between the first and second sample collection dates. Observed seroreversion was defined as a positive Total Ab test in Period 1 followed by a negative Total Ab test in Period 2.

Statistical analysis

Cumulative incidence estimates and 95% confidence intervals (95% CIs) were stratified by enrollment characteristics and risk factors acertained prior to specimen collection. Incidence proportions (observed seroconversions) were also stratified by risk factors measured prior to the date of specimen collection in Period 2. All data were cleaned and analyzed in R (version 4.0.3) and SAS (V9.4). Data were geocoded based on a self-reported ZIP code, and maps were created in ArcGIS 10.7. For categorical variables with missing data frequency <5%, we imputed missing data for participants using the most common value among all participants for a given variable.

Ethical Approval

The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY) Graduate School for Public Health and Health Policy.

RESULTS

The characteristics of the cohort are shown in Table 1, which includes participants from all 50 U.S. states, the District of Columbia, Puerto Rico, and Guam (see Fig. S1). Of the 6,745 participants enrolled in the cohort, 4,459 (66%) had at least one serologic test (Table 1). Compared with the entire cohort, those who underwent any serologic testing were older and more likely to be non-Hispanic White, college educated, and less likely to be healthcare workers or essential workers. 4,235 persons underwent serologic testing in Period 1, and 3,615 persons tested in Period 2. A total of 3,339 persons tested at both time points, including 3,280 who were seronegative on their antibody test in Period 1 and who could be followed prospectively for the

outcome of SARS-CoV-2 seroconversion based on their subsequent serologic test result in the study. Differences between those testing in Period 1 and Period 2 were negligible (Table S1). The median time between specimen collection dates for both serologic tests was 190 days (IQR 152-201) (Figure S2).

Table 1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants

	All participants		Participants with one or more serologic test	
	N	**%**	**N**	**%**
Total	6,745	100%	4459	66%
Age*				
Median (IQR)	37 (29,51)		41 (31, 55)	
18-29	1804	26.75	861	19.3
30-39	1965	29.13	1246	27.9
40-49	1160	17.2	846	19.0
50-59	792	11.74	646	14.5
60+	1024	15.18	860	19.3
Gender				
Male	3047	45.17	1991	44.7
Female	3527	52.29	2337	52.4
Non-Binary/Transgender	171	2.54	131	2.9
Race/Ethnicity*				
White Non-Hispanic	3859	56.8	2953	66.3
Hispanic	1310	19.42	669	15.0
Black Non-Hispanic	851	12.62	369	8.3
Asian	439	6.51	283	6.3
Pacific Islander	36	0.53	18	0.4
Other	250	3.71	167	3.8
Education				
Less than high school	123	1.82	52	1.2
High school graduate	879	13.03	399	9.0
Some college	1889	28.01	1126	25.3

College graduate	3854	57.14	2882	64.6
Employment*				
Employed	4249	62.99	2741	61.5
Out of work	830	12.31	535	12.0
Homemaker	352	5.22	240	5.4
Student	610	9.04	362	8.1
Retired	704	10.44	581	13.0
Household income*				
Less than $35,000	2180	32.32	1288	28.9
$35-49,999	753	11.16	487	10.9
$50-69,999	960	14.23	635	14.2
$70-99,999	1058	15.69	734	16.5
$100,000+	1794	26.6	1315	29.5
Setting*				
Urban	2974	44.09	1962	44.0
Suburban	1760	26.09	1143	25.6
Rural	2011	29.81	1354	30.4
Geographic region*				
Northeast	1882	27.9	1294	29.0
Midwest	1127	16.71	794	17.8
South	2103	31.18	1269	28.5
West	1625	24.09	1097	24.6
US Dependent Territories	8	0.12	5	0.1
Healthcare worker*				
No	5948	88.18	4042	90.7
Yes	797	11.82	417	9.4
Essential worker				
No	5601	83	3858	86.5
Yes	1144	17	601	13.5
Higher risk for severe COVID**				
No	3167	46.95	2074	46.5
Yes	3578	53.05	2385	53.5

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

** >60 years old, or reported co-morbidity, or current smoker.

Cumulative incidence since the beginning of the pandemic and potential risk factors

The crude and adjusted serology-based estimates of cumulative incidence of SARS-CoV-2 infection through the end of observation (January 31, 2021) were 6.8% (95% CI 6.1%-7.6%) and 6.3% (95% CI 5.5%-7.1%), respectively (Table S2). Cumulative incidence rates declined in dose-response fashion with increasing age, with substantially lower incidence in those aged 60 years and older (Figure 1). Higher cumulative incidence estimates were observed among males (7.8%, 95% CI 6.6%-9.0%), Hispanics 10.2% (95% CI 7.8%-12.6%), non-Hispanic Blacks (7.9%, 95% CI 5%-10.8%), those with a high school education (9.1%, 95% CI 0.9-20.9) or less (8.0%, 95% CI 5.2-10.9%), and those in the Northeast (7.8%, 95% CI 6.3%-9.4%). Lower cumulative incidence estimates were observed among persons aged 60 years and over (3.8%, 95% CI 2.5%-5.2%), those whose gender identity was non-binary (2.5%, 95% CI 0.4%-5.5%), and those who were retired (3.4%, 95% CI 1.7%-4.9%).



Figure 1 shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 by baseline demographic characteristics of CHASING COVID Cohort Study participants. Estimates are adjusted for laboratory test error. Essential workers include people working in in law enforcement, emergency management, delivery, transportation, and construction. High risk group is defined as participants who either reported a comorbidity, were over 60 years old, or were a smoker. The size of the square box/marker is proportional to the overall sample size in each group.

The estimated cumulative incidence of SARS-CoV-2 infection by epidemiologic risk factors reported at enrollment are shown in Figure 2 (and in Table S3). Higher cumulative incidence estimates were observed among those who, at cohort enrollment, reported having attended mass gatherings (8.6%, 95% CI 5.8%-12.4%), and lived in more crowded households (8.7%, 95% CI 5.7%-13.2%). Those who thought they had COVID-19 in the past, and in Period 2, those who had a known SARS-CoV-2 exposure, sought a test, had a self-reported SARS-CoV-2 diagnosis or COVID-19-related hospitalization also had markedly higher cumulative incidence (Table S3). People living with HIV had the highest cumulative incidence among those with comorbidities (8.8%, 95% CI 5.5%-13.6%) over the entire study period, however, those with diabetes had the highest cumulative incidence in Period 2 (Table S3). In terms of other potential risk factors, those who reported recently drinking more than 6 alcoholic drinks on one occasion (9.9%, 95% CI 6.6%-14.3%) and those who used public transportation (8.6%, 95% CI 5.7%-12.6%) had higher cumulative incidence (Fig. 2, Table S3). Lower cumulative incidence was observed among those who, at enrollment, reported having asthma, immunosuppression, and depression.



Figure 2 shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 in CHASING COVID Cohort Study participants by risk factors. Estimates are adjusted for laboratory test kit error. All risk factors were measured at the baseline survey. Alcohol use is defined as having

more than 6 drinks on one occasion weekly, daily, or almost daily. (NPIs: Non-pharmaceutical interventions; HH: Household). The size of the square box/marker is proportional to the overall sample size in each group.

Incidence of recent SARS-CoV-2 seroconversion and potential risk factors

Figure 3 (and Table S4) shows more recent seroconversions and incidence rates among 3,280 initially seronegative persons who had a subsequent serologic test during November 2020-January 2021 (Fig. S2), stratified by risk factors that were present prior to or between serologic tests. There were 145 observed seroconversions over 1,562 person years of follow-up among the 3,280 participants, for an overall incidence rate of 9.3 per 100 person years (PY) (95% CI 7.9-11.0). The rate ratio (RR) for incident SARS-CoV-2 infection was higher for males than females (RR: 1.34, 95% CI 0.96-1.87), Hispanics (RR: 2.11, 95% CI 1.40-3.12) and non-Hispanic Blacks (RR 1.79, 95% CI 0.96-3.13) compared with non-Hispanic Whites. In contrast to cumulative incidence estimates, incidence rates reflecting more recent seroconversions were higher among those in rural versus urban areas (RR 1.52, 95% CI 1.04-2.22), those in the Midwest (RR 1.62, 95% CI 0.98-2.69), the South (RR 1.73, 95% CI 1.1-2.75), and the West (RR 1.34, 95% CI 0.79-2.2) compared to the Northeast. Of note, essential workers had higher incidence than non-essential workers (RR 1.65, 95% CI 1.09--2.46).



Figure 3 shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING COVID Cohort Study participants by demographic factors. Essential workers include people working in in law enforcement, emergency management, delivery, transportation, and construction. High risk group is defined as participants who either reported a comorbidity, were over 60 years old, or were a smoker. The size of the square box/marker is proportional to the overall sample size in each group.

Figure 4 (and Table S5) shows recent seroconversions and incidence rates for epidemiologic risk factors. Living in more crowded households was associated with higher incidence than living in less crowded households (RR 1.61, 95% CI 1.08-2.32). Compared with referent groups in Figure 4, there was also higher incidence among those who dined indoors at restaurants/bars (RR 1.95, 95% CI 1.38-2.83); those who visited a place of worship (RR 1.95, 95% CI 1.25-2.93); those who wore a mask only sometimes while grocery shopping (RR 2.49, 95% CI 1.31-4.36); those who visited indoors with people not in their own household while always wearing a mask (RR=2.6; 95% CI 1.6-4.4), while sometimes wearing a mask (RR=3.5; 95% CI 2.7-5.7 or while never wearing a mask (RR=5.3; 95% CI 3.1-8.9); those working indoors at a place of employment while always wearing a mask (RR=2.0, 95% CI 1.4-2.8), while sometimes wearing a mask (RR=2.0, 95% CI 1.1-3.5), or while never wearing a mask RR=3.7, 95% CI 1.3-8.5); those attending a salon or gym with masks (RR=1.7, 95% CI 1.1-2.4); those who gathered indoors and outdoors in groups of >10 (RR=1.9, 95% CI 1.2-2.0); and those that traveled by air during the pandemic (RR 1.72, 95% CI 1.12-2.55).



Figure 4 shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING COVID Cohort Study participants by behavioral risk factors. For indoor mask use behavior, participants that did not engage in the respective behaviors were classified as N/A. The size of the square box/marker is proportional to the overall sample size in each group.

Clinical and public health outcomes among persons with serologic evidence of SARS-CoV-2 infection

Among the 303 individuals who were positive for Total Ab during the study, only 121 (39.9%) were aware that they had a prior SARS-CoV-2 infection (Table S6). A substantial proportion of the 303 (27.4%) recalled no symptoms of COVID-like illness (i.e., were asymptomatic cases). Among the 145 more recent seroconverters in Period 2, the proportion reporting no symptoms was 25.5%, and another 60% reported milder symptoms that did not result in seeking care.

In terms of public health outcomes, 64.4% (195/303) said that they were tested for SARS-CoV-2 outside the study (Table S6), half of them (32% of total) reported having a positive SARS-CoV-2 test. However, only 30.7% of all 303 seropositives said that they had isolated themselves from people outside their household because of their infection, and, among those who did not live alone, even fewer (13.5% overall) said they isolated themselves from others within their household. In terms of contact tracing, 17.8% of all seropositives were asked about

contacts following diagnosis and only 12.2% of all seropositives had been informed by a contact tracer that they may have had contact with someone confirmed to have SARS-CoV-2. Only 5.3% of those diagnosed (3.3% of all seropositives) were told by a contact tracer to stay home for a period of time because they had COVID-19.

Repeat serologic testing outcomes

A total of 303 persons who were ever seropositive by the Total Ab test contributed 392 seropositive Total Ab test results over the course of the study (Table S7). This included 134 persons with a positive Total Ab test in Period 1 and 258 in Period 2. Of the 258 Total Ab positives in Period 2, 145 were recent seroconverters. There were 20 individuals who were Total Ab positive in Period 1 but Total Ab negative in Period 2 (i.e., seroreverters and/or false positives). Specifically, of 134 persons who tested Total Ab positive in Period 1 and had a second test in Period 2, only 114 (85%) were still seropositive in Period 2. The median time between specimen collection for these 20 individuals was 197 days (IQR 187-201 days). Of the 392 specimens that were positive on the Total Ab test from Period 1 or 2, 361 had sufficient specimen quantity for further testing. Of these, 63.4% (201/361) were also positive on the spike protein-based IgG test, including 65.7% (88/127) in Period 1, and 42.1% (113/234) in Period 2 (Table S7).

DISCUSSION

We report findings from one of the first community-based prospective epidemiologic studies of SARS-CoV-2 incidence and risk factors, globally. We have prospectively characterized the risk of incident SARS-CoV-2 infection in relation to a range of modifiable risk factors in the U.S., using information on both past infection and recent seroconversion. With a well-characterized sample of participants with evidence of prior infection, our study suggests that public health strategies being widely used with the aim of reducing onward transmission (quarantine, testing, isolation, and contact tracing) do not have high enough coverage during the infectious period of SARS-CoV-2 to be effective at controlling community spread.

These are among the principal reasons why the U.S. has seen unmitigated increases in community transmission, hospitalizations, and deaths from COVID-19. Unless and until herd immunity can be achieved through a combination of natural infection and vaccine-induced

immunity, more nuanced understanding of the actual contribution of these factors over time is needed. This in turn will facilitate more effective government and community public health policies, actions and implementation strategies to control community spread, which is key to preventing avoidable hospitalizations and deaths, and ultimately maximizing the impact of vaccines. In areas where there is not an enforced lock down, our findings provide an evidence-base for federal, state, and local policy focus on risk factors that appear to be potential drivers of late-phase pandemic spread, such as indoor dining, mass gatherings, or not wearing masks when outside the home.

Data on more recent seroconversions occurring between May 2020 and January 2021 in our cohort suggest that elevated risk among essential workers, observed early in the U.S. pandemic, has persisted. Essential workers risk exposure to SARS-CoV-2 not only in their workplace(s), but also in their communities and as part of their commutes to and from work if they need to use public transportation. The increased burden of risk of SARS-CoV-2 infection in essential workers is then shared with their household members, among whom transmission is very efficient.[19] Along with this comes a higher burden of stress and anxiety among essential workers.[20] The most immediate action that governments can take to help keep essential workers safe is to minimize community transmission so that they are less likely to be exposed in the workplace or as part of their commutes. Policies and other strategies should be considered and implemented to ensure workplace safety (high quality masks, distancing, ventilation, paid sick leave for those that cannot afford to miss work) and the safety of public transportation. Any strategies should include prioritized access to SARS-CoV-2 vaccines for essential workers and, until or in the absence of vaccination, rapid testing for essential workers and members of their households. FDA-approved fully at-home rapid testing options are becoming more readily available with or without a prescription, and past research has indicated an overall increase in the uptake of testing with the addition of at-home testing options,[21,22] making them a potentially important strategy to increase early identification of new infections and subsequent interventions to prevent onward transmission. In this later phase of the pandemic, healthcare workers in our cohort had borderline elevated risk. Healthcare workers in the U.S. could be expected to have lower risk of SARS-CoV-2 exposure in the workplace due to focused efforts to mitigate risk via improved access to personal protective equipment and engineering controls. However, healthcare

workers also have ongoing community exposure, including possibly during their commutes to and from work, that could put them at higher risk of SARS-CoV-2 exposure and acquisition.

Our study provides epidemiologic evidence of increased risk for a number of key exposures. Living in more crowded households, defined as living in a multi-unit (i.e., apartment) building with 4 or more household members, was associated with a 60% higher incidence of SARS-CoV-2 infection compared with those living in less crowded households. Household transmission of SARS-CoV-2 occurs with very high attack rates, and may also increase the risk of more severe COVID-19 disease, requiring hospitalization.[23] Household crowding, more than population density, was shown to be a characteristic of community transmission 'hotspots' in a recent ecological analysis from the early phase of the pandemic.[24] When there are possible or confirmed cases of SARS-CoV-2 among household members, when background community transmission is substantial, or when the possibility of exposure outside the household is high (e.g., essential workers), our study and others[25] suggest mask use in the household should be considered, especially when it is otherwise not possible to limit potential exposure and spread in the household by isolating or sequestering away from others. As the vaccine rollout continues, this is particularly important to protect unvaccinated household members who may be at high risk for a severe COVID-19 outcome.

We characterized the potential contribution of several other key risk factors, some of which have been, or could be, the focus of state and federal policies, including dining indoors at a restaurant/bar, visiting a place of worship, inconsistent mask use while grocery shopping or visiting non-household members indoors (especially without masks), visiting a salon/gym, gathering indoors in groups of 10 or more, and recent travel by airplane during the pandemic. Working indoors, even while always masking but especially while never wearing a mask, was strongly associated with higher infection rates. In addition to being potential individual policy focus areas, we note that all of these risks can be mitigated by social distancing, workplace safety, increased mask use, use of more effective masks (e.g., KN95), and use of more than one mask.[26–28]

Finally, detailed examination of 303 individuals with serologic evidence of past SARS-CoV-2 infection showed major gaps in the reach of public health interventions aimed at testing, self-isolation, and contact tracing for people with SARS-CoV-2 (and their contacts). Indeed, many with evidence of prior SARS-CoV-2 infection did not report a prior positive PCR test, and a

substantial proportion were asymptomatic, both greatly hindering the ability of public health efforts to control spread. Furthermore, few people who had evidence of prior SARS-CoV-2 infection in our study reported having been reached by contact tracers. When considering the large proportion of people with SARS-CoV-2 who have asymptomatic infection, undiagnosed infection (with or without symptoms), the low likelihood of diagnosis during the pre-symptomatic phase, the high number of new daily diagnoses and the often long delay between testing and return of results, contact tracing (a strategy that requires rapid response and action with high coverage early in the infectious period) is likely not a feasible strategy to control community spread in the U.S.. Limited public health resources may be better spent instead on messaging that emphasizes the importance of self-isolation after symptom onset or a positive test. Verbal, written and electronic (SMS text, email) messaging should occur at the time of the test, rather than after results are returned. In the event of a positive result, messaging at the time of testing should also include instructions to notify close contacts, including in workplaces, that they should quarantine and, if symptoms develop, self-isolate.

A shift in emphasis and resources away from contact tracing as a strategy to control community spread would provide much needed resources at the state and local level to facilitate more rapid and targeted delivery of vaccination, which has faltered in many areas to date. Many in our cohort, as across the U.S., are not yet vaccinated, not yet eligible for or are not currently willing to undergo vaccination[29], and will remain at risk for months to come. Accelerating vaccine rollout, especially among those at high risk for a severe SARS-CoV-2 outcome and essential workers, has the potential to save tens of thousands of lives.

All of the potential risk factors described in our study and the low uptake of public health strategies conspire to create a perpetually disparate burden of risk among Hispanic and non-Hispanic Black persons and essential workers, as well as their household members and their communities. Our study suggests these inequalities have not been addressed to date in the U.S., and the ultimate drivers, which relate to structural racism and possibly other factors, need to be unpacked by health departments and researchers.[30] There has been much research focused on comorbid medical conditions and other biologic factors that may increase the risk of SARS-CoV-2 acquisition or severity.[31–33] However, non-biological structural factors are the major drivers of COVID-19 infection and severe outcomes, and the inequities by race/ethnicity, occupation, geography, and income. These non-biological structural factors, such as household

crowding, the need to go to work to avoid income loss, and inequitable access to SARS-CoV-2 testing[34], create a disparate burden of SARS-CoV-2 exposure and incidence.[35] To date, no targeted strategies or policies have been deployed that aim to protect those who cannot afford missing work, including, but not only, essential workers. These disparities in SARS-CoV-2 exposure, incidence, hospitalization and death will likely be perpetuated and likely exacerbated by differential uptake of the COVID-19 vaccines, driven by potentially flawed implementation strategies that prevent equitable access to vaccination. It is incumbent upon public health leaders, decision makers, and policy makers to anticipate and proactively design pandemic response implementation strategies, including metrics, that account for and counteract the fundamental and prevailing structural forces that without fail will otherwise create, perpetuate, or exacerbate inequities in safety, health and well-being.[36–39]

Strengths of our cohort study include its prospective design, allowing direct observation of seroconversions and incident COVID-19 infection among those who had no serologic evidence of prior SARS-CoV-2 infection, with and without risk factors. Our cohort is also geographically and sociodemographically diverse, facilitating assessment of geographic differences and racial/ethnic disparities. We also measured and were able to estimate incidence rates associated with a range of relevant epidemiologic risk factors.

Our study also has limitations worth noting. Most research studies deployed in the middle of a pandemic, including ours, may produce biased estimates since they may not include complete information on participants who died from COVID-19, or were too sick or otherwise too busy to participate in the research activities, or enrolled but became lost to follow-up. Moreover, it is possible that those who thought they had SARS-CoV-2 or were tested outside the study may have been more or less likely to participate in follow-up serologic testing, which would lead our seroincidence estimates to be biased in either direction. However, there was no systematic difference between those who tested in Period 1 and Period 2 (Table S1). Separately, while we have corrected our cumulative incidence estimates for laboratory test error[18], the *observed* cumulative incidence in our cohort may be lower than the *true* cumulative incidence in our cohort because of waning of SARS-CoV-2 antibodies. Recent studies suggest waning of antibodies to both nucleocapsid and spike proteins[2], which combined with the timing of specimen collection relative to infection for many participants in our cohort (median of 190 days)[9], could mean that we have underestimated the true cumulative incidence. Next, as with any

observational cohort study, estimated associations between SARS-CoV-2 risk factors and incidence are subject to confounding. The crude associations we presented could be over- or underestimated, and also may vary by setting. For example, the effect of indoor dining may be different in areas of lower versus higher levels of community transmission. Our study also had limited statistical power due to our sample size and the relatively short duration of follow-up. Finally, while our study is well-suited to characterize the risks related to SARS-CoV-2 acquisition, it is less well-suited to examine factors related to onward transmission from participants who had SARS-CoV-2 infection. However, in lieu of this, we have endeavored to describe the coverage of public health-related outreach to persons in our cohort who had evidence of past SARS-CoV-2 infection and identified some areas in need of improvement, such as the need for improvements in the uptake of testing and self-isolation.

Conclusion

Modifiable risk factors and poor reach of public health strategies continue to drive transmission of SARS-CoV-2 across the U.S.. It is critical to address inequities in incidence, reduce risk factors, and improve the reach of public health strategies of testing and self-isolation in the vaccine era. Given the properties of the SARS-CoV-2 virus, including the substantial asymptomatic and pre-symptomatic phases during the SARS-CoV-2 infectious period, the magnitude of cases and the need to act quickly, contact tracing is not a viable public health strategy to control the spread of the pandemic in the U.S.. Our cumulative incidence estimates suggest that many in our cohort remain at risk for SARS-CoV-2, including those with risk factors for infection and severe disease. While SARS-CoV-2 vaccines will likely reduce the risk of COVID-19 disease and possibly SARS-CoV-2 acquisition substantially for this group, this will likely take some time due to both the pace of the vaccine rollout and vaccine hesitancy. The CHASING COVID Cohort Study will continue to monitor SARS-CoV-2 outcomes, including vaccine uptake, through December 2021.

CONTRIBUTORS

DN, MR, SGK, MMR, conceptualized the study. MR, MC and DN performed statistical analyses. DN and MR wrote the first draft of the paper. DN, MR, MC, SGK, and AP contributed

to interpreting the data, DN, RZ, MR, MC, SGK, WY, AB, CM, SK, AM, MMR, DW, AP, LW, CG and to the writing and revising of the manuscript, SGK, WY, AB, CM, SK, and DN contributed to data collection, cleaning and management. DN, SGK, MMR and CG contributed to obtaining funding for the research.

ACKNOWLEDGEMENTS

The authors wish to thank the participants of the CHASING COVID Cohort Study. We are grateful to you for your contributions to the advancement of science around the SARS-CoV-2 pandemic. We thank Prof. Patrick Sullivan and MTL for local validation work on the serologic assays for use with DBS that greatly benefited our study. We are also grateful to MTL Labs for processing specimen collection kits and serologic testing of our cohort's specimens.

FUNDING

Funding for this project is provided by The National Institute of Allergy and Infectious Diseases (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy, and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina Population Center).

REFERENCES

1. CDC, COVID Data Tracker (2020), (available at https://covid.cdc.gov/covid-data-tracker/).

2. K. L. Bajema, R. E. Wiegand, K. Cuffe, S. V. Patel, R. Iachan, T. Lim, A. Lee, D. Moyse, F. P. Havers, L. Harding, A. M. Fry, A. J. Hall, K. Martin, M. Biel, Y. Deng, W. A. Meyer 3rd, M. Mathur, T. Kyle, A. V. Gundlapalli, N. J. Thornburg, L. R. Petersen, C. Edens, Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern. Med.* (2020), doi:10.1001/jamainternmed.2020.7976.

3. F. J. Angulo, L. Finelli, D. L. Swerdlow, Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Netw Open*. **4**, e2033706 (2021).

4. H. Kalish, C. Klumpp-Thomas, S. Hunsberger, H. A. Baus, M. P. Fay, N. Siripong, J. Wang, J. Hicks, J. Mehalko, J. Travers, M. Drew, K. Pauly, J. Spathies, T. Ngo, K. M. Adusei, M. Karkanitsa, J. A. Croker, Y. Li, B. I. Graubard, L. Czajkowski, O. Belliveau, C. Chairez, K. Snead, P. Frank, A. Shunmugavel, A. Han, L. T. Giurgea, L. A. Rosas, R. Bean, R. Athota, A. Cervantes-Medina, M. Gouzoulis, B. Heffelfinger, S. Valenti, R. Caldararo, M. M. Kolberg, A. Kelly, R. Simon, S. Shafiq, V. Wall, S. Reed, E. W. Ford, R. Lokwani, J.-P. Denson, S. Messing, S. G. Michael, W. Gillette, R. P. Kimberly, S. E. Reis, M. D. Hall, D. Esposito, M. J. Memoli, K. Sadtler, Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States. *medRxiv* (2021), doi:10.1101/2021.01.27.21250570.

5. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. Ipekci, G. Salanti, N. Low, Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med.* **17**, e1003346 (2020).

6. H. J. Hutchins, B. Wolff, R. Leeb, J. Y. Ko, E. Odom, J. Willey, A. Friedman, R. H. Bitsko, COVID-19 Mitigation Behaviors by Age Group - United States, April-June 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 1584–1590 (2020).

7. M. Lipsitch, D. L. Swerdlow, L. Finelli, Defining the epidemiology of Covid-19—studies

needed. *N. Engl. J. Med.* **382**, 1194–1196 (2020).

8. D. P. Oran, E. J. Topol, The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. *Ann. Intern. Med.* (2021), doi:10.7326/M20-6976.

9. M. Robertson, S. Kulkarni, A. Berry, C. Mirzayi, A. R. Maroko, R. Zimba, D. Westmoreland, C. Grov, A. Parcesepe, L. Waldron, D. Nash, A national prospective cohort study of SARS/COV2 pandemic outcomes in the U.S.: The CHASING COVID Cohort. *medRxiv (2020)*, doi:10.1101/2020.04.28.20080630.

10. C. Grov, D. A. Westmoreland, P. B. Carneiro, M. Stief, C. MacCrate, C. Mirzayi, D. W. Pantalone, V. V. Patel, D. Nash, Recruiting vulnerable populations to participate in HIV prevention research: findings from the Together 5000 cohort study. *Annals of Epidemiology*. **35** (2019), pp. 4–11.

11. D. Nash, M. Stief, C. MacCrate, C. Mirzayi, V. V. Patel, D. Hoover, D. W. Pantalone, S. Golub, G. Millett, A. B. D'Angelo, D. A. Westmoreland, C. Grov, A Web-Based Study of HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for an Observational Cohort Study. *JMIR Research Protocols*. **8** (2019), p. e13715.

12. C. Grov, D. Westmoreland, H. J. Rendina, D. Nash, Seeing Is Believing? Unique Capabilities of Internet-Only Studies as a Tool for Implementation Research on HIV Prevention for Men Who Have Sex With Men: A Review of Studies and Methodological Considerations. *J. Acquir. Immune Defic. Syndr.* **82 Suppl 3**, S253–S260 (2019).

13. CDC - BRFSS (2020), (available at https://www.cdc.gov/brfss/index.html).

14. T. A. Santibanez, J. A. Singleton, S. S. Santibanez, P. Wortley, B. P. Bell, Socio-demographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal influenza vaccination and disease among adults during the 2009--2010 influenza season. *Influenza Other Respi. Viruses*. **7**, 383–392 (2013).

15. S. Kumar, S. C. Quinn, K. H. Kim, L. H. Daniel, V. S. Freimuth, The impact of workplace policies and other social factors on self-reported influenza-like illness incidence during the

2009 H1N1 pandemic. *Am. J. Public Health*. **102**, 134–140 (2012).

16. M. T. Niles, R. Neff, E. Biehl, F. Bertmann, E. H. Morgan, T. Wentworth, Food Access and Security During Coronavirus Survey- Version 1.0 (2020), , doi:10.7910/DVN/RQ6NMG.

17. Center for Devices, Radiological Health, EUA Authorized Serology Test Performance (2021), (available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance).

18. C. T. Sempos, L. Tian, Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error. *Am. J. Epidemiol.* **190**, 109–115 (2021).

19. Z. J. Madewell, Y. Yang, I. M. Longini Jr, M. E. Halloran, N. E. Dean, Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open*. **3**, e2031756 (2020).

20. A. M. Parcesepe, M. Robertson, A. Berry, A. Maroko, R. Zimba, C. Grov, D. Westmoreland, S. Kulkarni, M. Rane, W. Salgado-You, C. Mirzayi, L. Waldron, D. Nash, The relationship between anxiety, health, and potential stressors among adults in the United States during the COVID-19 pandemic. *medRxiv* (2020), doi:10.1101/2020.10.30.20221440.

21. R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. Parcesepe, L. Waldron, M. Rane, S. Kochhar, M. Robertson, A. Maroko, C. Grov, D. Nash, SARS-CoV-2 Testing Service Preferences of Adults in the United States: Discrete Choice Experiment. *JMIR Public Health Surveill*. **6**, e25546 (2020).

22. M. L. Romo, R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. M. Parcesepe, L. Waldron, M. Rane, S. Kochhar, M. Robertson, A. R. Maroko, C. Grov, D. Nash, Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States. *medRxiv* (2020), doi:10.1101/2020.12.22.20248747.

23. D. Nash, S. Qasmieh, M. Robertson, M. Rane, R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. Parcesepe, L. Waldron, S. Kochhar, A. R. Maroko, C. Grov, Household factors and the risk of severe COVID-like illness early in the US pandemic.

medRxiv (2020), doi:10.1101/2020.12.03.20243683.

24. A. Maroko, D. Nash, B. Pavlonis, Covid-19 and Inequity: A comparative spatial analysis of New York City and Chicago hot spots. *J. Urban Health* (2020).

25. Y. Wang, H. Tian, L. Zhang, M. Zhang, D. Guo, W. Wu, X. Zhang, G. L. Kan, L. Jia, D. Huo, B. Liu, X. Wang, Y. Sun, Q. Wang, P. Yang, C. R. MacIntyre, Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health*. **5** (2020), doi:10.1136/bmjgh-2020-002794.

26. CDC, Scientific brief: Community use of cloth masks to control the spread of SARS-CoV-2 (2020), (available at https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html).

27. Y. Li, M. Liang, L. Gao, M. Ayaz Ahmed, J. P. Uy, C. Cheng, Q. Zhou, C. Sun, Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. *Am. J. Infect. Control* (2020), doi:10.1016/j.ajic.2020.12.007.

28. D. K. Chu, E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schünemann, COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*. **395**, 1973–1987 (2020).

29. K. A. Fisher, S. J. Bloomstone, J. Walder, S. Crawford, H. Fouayzi, K. M. Mazor, Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann. Intern. Med.* **173**, 964–973 (2020).

30. L. N. Borrell, J. R. Elhawary, E. Fuentes-Afflick, J. Witonsky, N. Bhakta, A. H. B. Wu, K. Bibbins-Domingo, J. R. Rodríguez-Santana, M. A. Lenoir, J. R. Gavin 3rd, R. A. Kittles, N. A. Zaitlen, D. S. Wilkes, N. R. Powe, E. Ziv, E. G. Burchard, Race and Genetic Ancestry in Medicine - A Time for Reckoning with Racism. *N. Engl. J. Med.* **384**, 474–480 (2021).

31. A. Emami, F. Javanmardi, N. Pirbonyeh, A. Akbari, Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Archives of*

academic emergency medicine. **8** (2020) (available at https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7096724/).

32. S. Richardson, J. S. Hirsch, M. Narasimhan, J. M. Crawford, T. McGinn, K. W. Davidson, the Northwell COVID-19 Research Consortium, D. P. Barnaby, L. B. Becker, J. D. Chelico, S. L. Cohen, J. Cookingham, K. Coppa, M. A. Diefenbach, A. J. Dominello, J. Duer-Hefele, L. Falzon, J. Gitlin, N. Hajizadeh, T. G. Harvin, D. A. Hirschwerk, E. J. Kim, Z. M. Kozel, L. M. Marrast, J. N. Mogavero, G. A. Osorio, M. Qiu, T. P. Zanos, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. **323**, 2052–2059 (2020).

33. C. M. Petrilli, S. A. Jones, J. Yang, H. Rajagopalan, L. O'Donnell, Y. Chernyak, K. A. Tobin, R. J. Cerfolio, F. Francois, L. I. Horwitz, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*. **369**, m1966 (2020).

34. A. Mody, K. Pfeifauf, E. H. Geng, Using Lorenz Curves to Measure Racial Inequities in COVID-19 Testing. *JAMA Netw Open*. **4**, e2032696 (2021).

35. G. Ogedegbe, J. Ravenell, S. Adhikari, M. Butler, T. Cook, F. Francois, E. Iturrate, G. Jean-Louis, S. A. Jones, D. Onakomaiya, C. M. Petrilli, C. Pulgarin, S. Regan, H. Reynolds, A. Seixas, F. M. Volpicelli, L. I. Horwitz, Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City. *JAMA Netw Open*. **3**, e2026881 (2020).

36. D. Nash, E. Geng, Goal-Aligned, Epidemic Intelligence for the Public Health Response to the COVID-19 Pandemic. *Am. J. Public Health*. **110**, 1154–1156 (2020).

37. D. Nash, Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the Public Health Threat Posed by HIV Epidemics. *Am. J. Public Health*. **110**, 53–57 (2020).

38. Z. D. Bailey, J. M. Feldman, M. T. Bassett, How Structural Racism Works - Racist Policies as a Root Cause of U.S. Racial Health Inequities. *N. Engl. J. Med.* (2020), doi:10.1056/NEJMms2025396.

39. Z. D. Bailey, N. Krieger, M. Agénor, J. Graves, N. Linos, M. T. Bassett, Structural racism and health inequities in the USA: evidence and interventions. *Lancet*. **389**, 1453–1463 (2017).

SUPPLEMENTAL MATERIALS



Fig. S1.
Geographic distribution of CHASING COVID Cohort participants, N=6,745



Fig. S2.

Timing of first (red) and second (blue) dried blood spot specimen collection in the CHASING COVID Cohort Study, including follow-up interview milestones

Table S1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

	All participants		Participants with one or more serologic test		Participants with a serologic test in Period 1 (May-September 2020)		Participants with a serologic test in Period 2 (November 2020-January 2021)*	
	N	**%**	**N**	**%**	**N**	**%**	**N**	**%**
Total	6,745	100%	4459	66%	4235	63%	3615	54%
Age*								
Median (IQR)	37 (29,51)		41 (31, 55)		41, (32, 56)		41, (32, 56)	
18-29	1804	26.75	861	19.3	801	18.9	656	18.4
30-39	1965	29.13	1246	27.9	1177	27.8	1004	27.8
40-49	1160	17.2	846	19.0	809	19.1	686	19.0
50-59	792	11.74	646	14.5	620	14.6	541	15.0
60+	1024	15.18	860	19.3	828	19.6	719	19.9
Gender								
Male	3047	45.17	1991	44.7	1900	44.9	1607	44.5
Female	3527	52.29	2337	52.4	2212	52.2	1906	52.7
Non-Binary/Transgender	171	2.54	131	2.9	123	2.9	102	2.8
Race/Ethnicity*								
Non-Hispanic White	3859	56.8	2953	66.3	2833	66.9	2410	66.7
Hispanic	1310	19.42	669	15.0	623	14.7	550	15.2
Non-Hispanic Black	851	12.62	369	8.3	342	8.1	285	7.9
Asian	439	6.51	283	6.3	262	6.2	228	6.3
Pacific Islander	36	0.53	18	0.4	18	0.4	15	0.4
Other	250	3.71	167	3.8	157	3.7	127	3.5
Education								
Less than high school	123	1.82	52	1.2	47	1.1	43	1.2
High school graduate	879	13.03	399	9.0	367	8.7	308	8.5
Some college	1889	28.01	1126	25.3	1053	24.9	871	24.1

College graduate	3854	57.14	2882	64.6	2768	65.4	2393	66.2
Employment*								
Employed	4249	62.99	2741	61.5	2613	61.7	2216	61.3
Out of work	830	12.31	535	12.0	503	11.9	429	11.9
Homemaker	352	5.22	240	5.4	225	5.3	194	5.4
Student	610	9.04	362	8.1	330	7.8	283	7.8
Retired	704	10.44	581	13.0	564	13.3	493	13.6
Household income*								
Less than $35,000	2180	32.32	1288	28.9	1213	28.6	1009	27.9
$35-49,999	753	11.16	487	10.9	457	10.8	402	11.1
$50-69,999	960	14.23	635	14.2	600	14.2	532	14.7
$70-99,999	1058	15.69	734	16.5	706	16.7	624	17.3
$100,000+	1794	26.6	1315	29.5	1259	29.7	1048	29.0
Setting*								
Urban	2974	44.09	1962	44.0	1873	44.2	1572	43.5
Suburban	1760	26.09	1143	25.6	1092	25.8	928	25.7
Rural	2011	29.81	1354	30.4	1270	30.0	1115	30.8
Geographic region*								
Northeast	1882	27.9	1294	29.0	1244	29.4	1023	28.3
Midwest	1127	16.71	794	17.8	760	18.0	655	18.1
South	2103	31.18	1269	28.5	1188	28.1	1037	28.7
West	1625	24.09	1097	24.6	1038	24.5	896	24.8
US Dependent Territories	8	0.12	5	0.1	5	0.1	4	0.1
Healthcare worker*								
No	5948	88.18	4042	90.7	3835	90.6	3283	90.8
Yes	797	11.82	417	9.4	400	9.5	332	9.2
Essential worker								
No	5601	83	3858	86.5	3662	86.5	3137	86.8
Yes	1144	17	601	13.5	573	13.5	478	13.2
Higher risk for severe COVID**								
No	3167	46.95	2074	46.5	1974	46.6	1669	46.2
Yes	3578	53.05	2385	53.5	2261	53.4	1946	53.8

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common

value for this variable
** >60 years old, or reported co-morbidity, or current smoker.

Table S1.

Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

Table S2. Crude and adjusted** cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing

	All unique participants with a serologic test result (Period 1 or Period 2) N=4,459				**Participants with a serologic test in Period 1 (N=4,235)**				**Participants with a serologic test in Period 2 (N=3,615)**			
	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)
Total	**303**	**4459**	**6.8 (6.1, 7.6)**	**6.3 (5.5, 7.1)**	**134**	**4235**	**3.2 (2.6, 3.7)**	**2.6 (2, 3.1)**	**258**	**3615**	**7.2 (6.3, 8)**	**6.7 (5.8, 7.5)**
Age group*												
18-29	66	861	7.7 (5.9, 9.4)	7.2 (5.3, 8.9)	28	801	3.5 (2.2, 4.8)	2.4 (1.1, 3.7)	57	665	8.6 (6.4, 10.7)	7.6 (5.4, 9.7)
30-39	94	1246	7.5 (6.1, 9.0)	7 (5.5, 8.5)	46	1177	3.9 (2.8, 5.0)	2.8 (1.7, 4)	76	1004	7.6 (5.9, 9.2)	6.6 (4.9, 8.2)
40-49	60	846	7.1 (5.4, 8.8)	6.6 (4.8, 8.3)	27	809	3.3 (2.1, 4.6)	2.2 (1, 3.5)	47	686	6.9 (5, 8.7)	5.9 (3.9, 7.7)
50-59	45	646	7.1 (5.1, 9.1)	6.6 (4.5, 8.6)	20	620	3.4 (2, 4.8)	2.3 (0.9, 3.7)	44	541	8.3 (6, 10.6)	7.3 (5, 9.6)
60+	38	860	4.4 (3.1, 5.8)	3.8 (2.5, 5.2)	13	828	1.6 (0.7, 2.4)	0.5 (0, 1.3)	34	719	4.7 (3.2, 6.3)	3.6 (2.1, 5.3)
Gender												
Male	165	1991	8.3 (7.1, 9.5)	7.8 (6.6, 9)	79	1900	4.2 (3.3, 5.1)	3.1 (2.2, 4)	134	1607	8.3 (7, 9.7)	7.3 (6, 8.7)
Female	134	2337	5.8 (4.8, 6.7)	5.2 (4.2, 6.2)	54	2212	2.5 (1.8, 3.1)	1.4 (0.7, 2)	120	1906	6.4 (5.3, 7.4)	5.4 (4.2, 6.4)
Non-Binary/Transgender	4	131	3.1 (1.1, 6.1)	2.5 (0.4, 5.5)	1	123	0.8 (0, 2.4)	0 (0, 1.3)	4	102	3.9 (1.5, 7.7)	2.8 (0, 6.7)
Race/Ethnicity*												
Non-Hispanic White	174	2953	5.9 (5.1, 6.8)	5.3 (4.5, 6.3)	81	2833	2.9 (2.3, 3.5)	1.8 (1.2, 2.4)	156	2410	6.5 (5.5, 7.5)	5.5 (4.4, 6.5)
Hispanic	71	669	10.6 (8.3, 13.0)	10.2 (7.8, 12.6)	26	623	4.2 (2.6, 5.8)	3.1 (1.5, 4.8)	57	550	10.4 (7.8, 12.9)	9.4 (6.8, 11.9)
Non-Hispanic Black	31	369	8.4 (5.6, 11.2)	7.9 (5, 10.8)	13	342	3.8 (1.8, 5.8)	2.7 (0.7, 4.8)	25	285	8.8 (5.5, 12.1)	7.8 (4.4, 11.1)
Asian	16	283	5.7 (3.0, 8.3)	5.1 (2.4, 7.8)	9	262	3.4 (1.2, 5.6)	2.3 (0.1, 4.6)	12	228	5.3 (2.4, 8.2)	4.2 (1.3, 7.2)
Pacific Islander	0	18	0 (0, 0)		0	18	0 (0, 17.6)	0 (0, 16.7)	0	15		
Other	11	167	6.6 (3.7, 11.4)	6.1 (3.1, 11)	5	157	3.2 (0.4, 5.9)	2.1 (0, 4.9)	8	127	6.3 (2.1, 10.5)	5.3 (1, 9.5)
Education												
Less than high school	5	52	9.6 (1.6, 21.0)	9.1 (0.9, 20.9)	3	47	6.4 (0, 13.4)	5.4 (0, 12.4)	3	43	7 (0, 14.6)	6 (0, 13.7)
High school graduate	34	399	8.5 (5.8, 11.3)	8 (5.2, 10.9)	13	367	3.5 (1.7, 5.4)	2.4 (0.6, 4.3)	29	308	9.4 (6.2, 12.7)	8.4 (5.2, 11.7)
Some college	72	1126	6.4 (5.0, 7.8)	5.9 (4.4, 7.3)	29	1053	2.8 (1.8, 3.8)	1.7 (0.7, 2.7)	62	871	7.1 (5.4, 8.8)	6.1 (4.3, 7.8)
College graduate	192	2882	6.7 (5.8, 7.6)	6.2 (5.2, 7.1)	89	2768	3.3 (2.6, 3.9)	2.2 (1.5, 2.8)	164	2393	6.9 (5.8, 7.9)	5.9 (4.8, 6.9)
Employment*												
Employed	208	2741	7.6 (6.6, 8.6)	7.1 (6.1, 8.1)	95	2613	2.4 (1.5, 3.4)	1.3 (0.4, 2.3)	179	2216	8.1 (6.9, 9.2)	7.1 (5.9, 8.2)
Out of work	34	535	6.4 (4.3, 8.4)	5.9 (3.7, 7.9)	15	503	1.9 (0.1, 3.7)	0.8 (0, 2.6)	26	429	6.1 (3.8, 8.3)	5.1 (2.7, 7.3)

Homemaker	14	240	6.2 (3.2, 9.3)	5.7 (2.6, 8.8)	6	225	3.5 (0.5, 6.4)	2.4 (0, 5.4)	11	194	6.2 (3, 9.5)	5.2 (1.9, 8.5)
Student	24	362	6.7 (4.1, 9.2)	6.2 (3.5, 8.7)	10	330	2 (0, 4.7)	0.9 (0, 3.6)	21	283	7.4 (4.4, 10.5)	6.4 (3.3, 9.5)
Retired	23	581	4.0 (2.4, 5.5)	3.4 (1.7, 4.9)	8	564	1.2 (0, 2.6)	0.1 (0, 1.5)	21	493	4.3 (2.5, 6)	3.2 (1.4, 5)
Household income*												
Less than $35,000	82	1288	6.4 (5.1, 7.8)	5.9 (4.5, 7.3)	31	1213	2.3 (1.4, 3.1)	1.2 (0.3, 2)	71	1009	7.1 (5.5, 8.7)	6.1 (4.4, 7.7)
$35-49,999	40	487	8.2 (5.8, 10.6)	7.7 (5.2, 10.2)	17	457	3.7 (2, 5.4)	2.6 (0.9, 4.3)	34	402	8.5 (5.7, 11.2)	7.5 (4.7, 10.2)
$50-69,999	39	635	6.1 (4.3, 8.0)	5.5 (3.7, 7.5)	16	600	2.7 (1.4, 4)	1.6 (0.3, 2.9)	31	532	5.8 (3.8, 7.8)	4.8 (2.7, 6.8)
$70-99,999	57	734	7.8 (5.8, 9.7)	7.3 (5.2, 9.2)	26	706	3.7 (2.3, 5.1)	2.6 (1.2, 4)	49	624	7.9 (5.7, 9.9)	6.9 (4.7, 8.9)
$100,000+	85	1315	6.5 (5.1, 7.8)	6 (4.5, 7.3)	44	1259	3.5 (2.5, 4.5)	2.4 (1.4, 3.4)	73	1048	6 (5.4, 8.5)	5 (4.3, 7.5)
Setting*												
Urban	136	1962	6.9 (5.8, 8.1)	6.4 (5.2, 7.6)	71	1873	3.9 (3, 4.8)	2.8 (1.9, 3.7)	111	1572	7.1 (5.8, 8.3)	6.1 (4.8, 7.3)
Suburban	78	1143	6.8 (5.4, 8.3)	5.8 (4.3, 7.3)	35	1092	3.2 (2.2, 4.3)	2.1 (1.1, 3.2)	68	928	7.3 (5.7, 9)	6.3 (4.7, 8)
Rural	89	1354	6.7 (5.3, 8.0)	5.7 (4.2, 7)	28	1270	2.3 (1.5, 3.1)	1.2 (0.4, 2)	79	1115	7.2 (5.7, 8.7)	6.2 (4.7, 7.7)
Geographic region*												
Northeast	106	1294	8.3 (6.8, 9.8)	7.8 (6.3, 9.4)	72	1244	5.9 (4.6, 7.2)	4.9 (3.5, 6.2)	85	1023	8.4 (6.7, 10.1)	7.4 (5.7, 9.1)
Midwest	50	794	6.3 (4.6, 8.0)	5.8 (4, 7.5)	16	760	2.1 (1.1, 3.1)	1 (0, 2)	49	655	7.5 (5.5, 9.5)	6.5 (4.4, 8.5)
South	90	1269	7.2 (5.7, 8.6)	6.6 (5.2, 8.1)	31	1188	2.6 (1.8, 3.6)	1.5 (0.7, 2.5)	72	1037	6.9 (5.5, 8.6)	5.9 (4.4, 7.6)
West	57	1097	5.2 (3.9, 6.5)	4.6 (3.3, 6)	15	1038	1.5 (0.7, 2.2)	0.4 (0, 1.1)	52	896	5.8 (4.3, 7.3)	4.8 (3.2, 6.3)
US Dep	0	5	0 (0, 0)		0	5	0 (0, 0)	0 (0, 0)	0	4	0 (0, 0)	0 (0, 0)
Healthcare worker*												
No	274	4042	6.8 (6.0, 7.6)	6.3 (5.4, 7.1)	124	3835	3 (2.2, 3.7)	1.9 (1.1, 2.6)	233	3283	7.1 (6.3, 8)	6.1 (5.3, 7)
Yes	29	417	7.0 (4.5, 9.4)	6.5 (3.9, 8.9)	10	400	2.4 (0.1, 4.7)	1.3 (0, 3.6)	25	332	7.5 (4.7, 10.4)	6.5 (3.6, 9.4)
Essential worker												
No	257	3858	6.7 (5.9, 7.5)	6.2 (5.3, 7)	120	3662	3.3 (2.7, 3.9)	1.9 (1.3, 2.5)	218	3137	7 (6.1, 7.9)	6 (5.1, 6.9)
Yes	46	601	7.7 (5.5, 9.8)	7.2 (4.9, 9.4)	14	573	2.4 (1.2, 3.7)	3.3 (1.8, 4.9)	40	478	8.4 (5.9, 10.9)	7.4 (4.9, 9.9)
High Risk group***												
No	162	2074	7.8 (6.7, 9.0)	7.3 (6.2, 8.5)	79	1974	4.0 (3.1, 4.9)	3 (2.1, 3.9)	136	1669	8.2 (6.8, 9.5)	6.9 (5.6, 8.3)
Yes	141	2385	6.0 (5.0, 6.9)	5.4 (4.4, 6.4)	55	2261	2.5 (1.8, 3.1)	1.4 (0.8, 2)	122	1946	6.3 (5.2, 7.4)	5.1 (4, 6.2)

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

**Adjusted for laboratory test performance

*** >60 years old, or reported co-morbidity, or current smoker.

Table S2.

Crude and adjusted** cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing.

Table S3. Crude and adjusted* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

	All unique participants with a serologic test result (Baseline or follow-up) N=4,459				Participants with a serologic test in Period 1 (N=4,235)				Participants with a serologic test in Period 2 (N=3,615)			
	Positive test (Period 1 and/or Period 2)	Total participants	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Positive test	Total participants	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Positive Test	Total Participants	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)
Total	**303**	**4459**	**6.8 (6.1, 7.6)**	6.3 (5.5, 7.1)	**134**	**4235**	**3.1 (2.7, 3.7)**	**2.5 (2.1, 3.1)**	**258**	**3615**	**7.2 (6.3, 8)**	**6.7 (5.8, 7.5)**
Non-pharmaceutical interventions												
Did not use mask	15	217	6.9 (4.2, 11.1)	6.4 (3.6, 10.7)	3	200	1.5 (0.3, 4.3)	0.8 (0, 3.7)	14	274	5.1 (3.1, 8.4)	4.5 (2.5, 7.9)
Attended gatherings	27	299	9 (6.3, 12.8)	8.6 (5.8, 12.4)	9	284	3.1 (1.4, 5.9)	2.5 (0.7, 5.3)	98	1354	7.2 (5.9, 8.7)	6.7 (5.3, 8.2)
Attended Protests	-	-	-	-	-	-	-	-	11	169	6.5 (3.7, 11.3)	6 (3.1, 10.9)
Did not Self-Quarantine	98	1554	6.3 (5.2, 7.6)	5.8 (4.6, 7.1)	28	1481	1.9 (1.2, 2.7)	1.2 (0.5, 2.1)	211	3552	5.9 (5.2, 6.7)	5.3 (4.6, 6.2)
Decreased hand-washing	6	96	6.2 (2.9, 12.9)	5.7 (2.3, 12.5)	2	91	2.1 (0.2, 7.7)	1.4 (0, 7.2)	24	389	6.2 (4.2, 9)	5.7 (3.6, 8.5)
Household factors												
Child in household	77	1204	6.4 (5.1, 7.9)	5.9 (4.5, 7.4)	32	1126	2.8 (2, 4)	2.2 (1.3, 3.4)	62	961	6.4 (5.1, 8.2)	5.9 (4.5, 7.7)
Household crowding												
<4 persons in household	222	3356	6.6 (5.8, 7.5)	6.1 (5.2, 7)	103	3207	3.2 (2.6, 3.8)	2.6 (2, 3.2)	188	2732	6.8 (5.9, 7.9)	6.2 (5.3, 7.4)
4+ persons in single unit	56	834	6.7 (5.2, 8.6)	6.2 (4.6, 8.1)	22	744	2.8 (1.8, 4.2)	2.2 (1.1, 3.6)	48	671	7.1 (5.4, 9.3)	6.6 (4.8, 8.8)
4+ persons in multi unit	23	249	9.2 (6.2, 13.5)	8.7 (5.7, 13.2)	9	236	3.8 (2, 7.1)	3.2 (1.3, 6.6)	20	199	10.1 (6.6, 15)	9.7 (6.1, 14.7)
History of COVID infection and testing												
Thought had COVID	85	629	13.5 (11.1, 16.4)	13.2 (10.7, 16.1)	58	604	9.6 (7.5, 12.2)	9.1 (7, 11.8)	95	675	14.1 (11.6, 16.9)	13.8 (11.2, 16.6)
Known COVID exposure	-	-	-	-	-	-	-	-	27	205	13.2 (9.2, 18.5)	12.8 (8.7, 18.3)
Sought a test	-	-	-	-	-	-	-	-	169	1804	9.4 (8.1, 10.8)	8.9 (7.6, 10.4)
Self-reported positive diagnosis	-	-	-	-	-	-	-	-	82	182	45.1 (38, 52.3)	45.6 (38.3, 53)
Self-reported hospitalization	-	-	-	-	-	-	-	-	8	67	11.9 (6.2, 21.8)	11.5 (5.7, 21.7)
Knew someone who died	33	435	7.6 (5.4, 10.5)	7.1 (4.8, 10.1)	17	416	4.1 (2.5, 6.4)	3.5 (1.8, 5.9)	84	1213	6.9 (5.6, 8.5)	6.4 (5, 8)
No Insurance	55	663	8.3 (6.4, 10.6)	7.8 (5.9, 10.2)	23	616	3.7 (2.5, 5.5)	3.1 (1.8, 4.9)	80	1025	7.8 (6.3, 9.6)	7.3 (5.8, 9.1)
Comorbidities												
Asthma	42	745	5.6 (4.2, 7.5)	5 (3.6, 7)	15	686	2.1 (1.2, 3.5)	1.4 (0.5, 2.9)	35	745	4.7 (3.4, 6.5)	4.1 (2.8, 6)
Heart attack	4	53	7.6 (2.9, 17.8)	7 (2.3, 17.6)	1	50	1.9 (0.1, 10.4)	1.2 (-0.7, 10)	3	53	7.7 (2.6, 20.3)	7.2 (2, 20.1)

Immunosuppression	3	135	2.2 (0.7, 6.3)	1.6 (0, 5.8)	2	129	1.5 (0.2, 5.4)	0.8 (0, 4.8)	3	135	2.8 (0.9, 7.8)	2.1 (0.2, 7.3)
Depression	61	1056	5.7 (4.5, 7.3)	5.1 (3.9, 6.8)	16	995	1.6 (0.9, 2.5)	0.9 (0.2, 1.8)	55	1056	5.2 (4, 6.7)	4.6 (3.4, 6.2)
Diabetes	24	307	7.8 (5.3, 11.4)	7.3 (4.7, 11)	5	286	1.7 (0.5, 3.9)	1 (-0.2, 3.3)	24	307	7.8 (5.3, 11.4)	7.3 (4.7, 11)
HIV	20	214	9.3 (6.1, 13.9)	8.8 (5.5, 13.6)	7	192	3.5 (1.4, 7.1)	2.9 (0.7, 6.6)	17	214	7.9 (5.1, 12.4)	7.4 (4.5, 12)
Other potential risk factors												
Alcohol use**	26	253	10.3 (7.1, 14.6)	9.9 (6.6, 14.3)	9	233	3.7 (1.7, 6.9)	3.1 (1, 6.4)	26	340	7.6 (5.2, 10.9)	7.1 (4.6, 10.5)
Substance use***	-	-	-	-	-	-	-	-	37	607	6.1 (4.4, 8.3)	5.5 (3.8, 7.8)
Received Flu vaccine in 2019	136	1824	7.4 (6.3, 8.7)	6.9 (5.8, 8.2)	70	1751	4 (3.1, 5)	3.4 (2.5, 4.4)	114	1824	7.4 (6.1, 8.8)	6.9 (5.5, 8.3)
PrEP for HIV prevention	-	-	-	-	-	-	-	-	40	383	10.4 (7.7, 13.9)	10 (7.2, 13.6)
Pets in home	-	-	-	-	-	-	-	-	78	1382	5.6 (4.5, 7)	5 (3.9, 6.5)
Public transportation	25	276	9.1 (6.2, 13)	8.6 (5.7, 12.6)	11	258	4.2 (2.1, 7.5)	3.6 (1.4, 7)	87	1053	8.3 (6.7, 10.1)	7.8 (6.2, 9.7)
History of air travel during pandemic		-		-	-	-	-	-	56	701	7.9 (6.2, 10.2)	7.4 (5.7, 9.8)

Table S3.

Crude and adjusted* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

Table S4. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

	No. of seronegative participants in Period 1	**No. of incident infections**	**Total PY*** of follow up**	**Incidence rate per 100 PY*** (95% CI)**	**Rate Ratio (95% CI)**
Total	3280	145	1562.0	9.3 (7.9, 11.0)	-
Age group*					
18-29	584	33	280.5	11.8 (8.3, 16.7)	1.26 (0.79, 2)
30-39	902	40	428.8	9.3 (6.8, 12.8)	-ref-
40-49	626	31	294.7	10.5 (7.3, 15.1)	1.13 (0.7, 1.8)
50-59	494	20	237.1	8.4 (5.4, 13.2)	0.9 (0.52, 1.54)
60+	674	21	320.8	6.5 (4.2, 10.1)	0.7 (0.41, 1.18)
Gender					
Male	1453	77	711.6	10.8 (8.6, 13.6)	1.34 (0.96, 1.87)
Female	1734	65	803.2	8.1 (6.3, 10.4)	-ref-
Non-binary/Trans	93	3	43.1	7.0 (2.2, 22.0)	0.86 (0.21, 2.43)
Race/Ethnicity*					
White	2218	83	1085.4	7.6 (6.1, 9.5)	-ref-
Hispanic	485	34	210.9	16.1 (11.4, 22.8)	**2.11 (1.4, 3.12)**
Black	249	15	109.5	13.7 (8.1, 23.1)	1.79 (0.96, 3.13)
Asian	199	7	94.6	7.4 (3.5, 13.7)	0.97 (0.41, 1.99)
Pacific Islander	15	0	7.0	-	
Other	114	6	54.6	11.0 (4.8, 25.0)	1.44 (0.57, 3.1)
Education					
Less than HS	37	2	16.1	12.4 (3.0, 51.7)	1.47 (0.24, 4.98)
HS grad	268	13	115.2	11.3 (6.5, 19.7)	1.34 (0.72, 2.33)
Some college	774	39	353.0	11.0 (8.0, 15.2)	1.31 (0.89, 1.89)
Collge grad	2201	91	1077.6	8.4 (6.8, 10.4)	-ref-
Employment*					
Employed	2005	96	963.3	10.0 (8.1, 12.2)	-ref-
Out of work	387	17	179.5	9.5 (5.8, 15.4)	0.95 (0.55, 1.56)
Homemaker	176	6	77.2	7.8 (3.4, 17.6)	0.78 (0.31, 1.67)
Student	244	12	120.1	10.0 (5.6, 17.9)	1 (0.53, 1.78)
Retired	468	14	221.9	6.3 (3.7, 10.7)	0.63 (0.35, 1.08)
Household income*					
Less than $35,000	909	45	418.7	10.7 (8.0, 14.5)	1.44 (0.93, 2.26)
$35-49,999	361	19	168.8	11.3 (7.1, 17.9)	1.51 (0.85, 2.63)
$50-69,999	484	16	229.3	7.0 (4.2. 11.5)	0.94 (0.51, 1.68)
$70-99,999	574	30	275.7	10.9 (7.5. 15.7)	1.46 (0.89, 2.38)
$100,000+	952	35	469.5	7.5 (5.3, 10.4)	-ref-
Setting*					
Urban	1426	54	693.6	7.9 (5.9, 10.2)	-ref-
Suburban	846	36	404.3	8.9 (6.4, 12.4)	1.14 (0.74, 1.74)
Rural	1008	55	464.1	11.9 (9.0, 15.6)	**1.52 (1.04, 2.22)**
Geographic region*					
Northeast	910	30	447.6	6.7 (4.7, 9.6)	-ref-

Midwest	605	31	285.8	10.8 (7.6. 15.6)	1.62 (0.98, 2.69)
South	934	50	431.5	11.5 (8.7, 15.4)	**1.73 (1.1, 2.75)**
West	827	34	394.0	8.6 (6.1, 12.2)	1.29 (0.79, 2.12)
US Dep	4	0	2.0	0 (,)	0 (0, 11.75)
Healthcare worker*					
No	2973	129	1416.1	9.1 (7.6, 10.9)	-ref-
Yes	307	16	145.8	11.0 (6.6, 18.1)	1.2 (0.69, 1.98)
Essential worker					
No	2842	116	1356.8	8.5 (7.1, 10.3)	-ref-
Yes	438	29	205.1	14.1 (9.7, 20.6)	**1.65 (1.09, 2.46)**
High Risk group**					
No	1506	72	722.5	10.0 (7.9, 12.6)	-ref-
Yes	1774	73	839.5	8.7 (6.9, 11.0)	0.87 (0.63, 1.21)

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable
**>60 years old, or reported co-morbidity, or current smoker.
***PY = Person Years

Table S4.

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

Table S5. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

	No. of seronegative participants in Period 1	**No. of incident infections**	**Total PY of follow up**	**Incidence rate per 100 PY (95% CI)**	**Rate Ratio (95% CI)**
Total	3280	145	1562	9.3 (7.9, 10.8)	
Household factors					
Household crowding	785	35	259.38	13.5 (9.8, 18.1)	**1.61 (1.08, 2.32)**
No household crowding	2495	110	1302.62	8.4 (7.1, 10.1)	-ref-
Child in household	932	40	421.65	9.5 (7, 12.6)	1.03 (0.71, 1.47)
No child in household	2348	105	1140.37	9.2 (7.6, 11)	-ref-
No Confirmed case in household member	42	18	34.14	0.5 (0.32, 0.81)	-ref-
Confirmed case in household member	82	25	14.73	1.7 (1.1, 2.5)	3.2 (1.7, 6)
NA	3156	102	1513.15	0.1 (0.05, 0.08)	
Social distancing					
Attended mass gathering(s)	337	16	167.26	9.5 (5.9, 14.9)	1.03 (0.6, 1.7)
Did not attend mass gathering(s)	2943	129	1394.76	9.2 (7.8, 10.8)	-ref-
Indoor dining/bar	1787	102	854.15	11.9 (9.9, 14.3)	**1.95 (1.38, 2.83)**
No indoor dining/bar	1489	43	707.86	6.1 (4.5, 8.1)	-ref-
Outdoor dining/bar	1896	92	928.21	9.7 (7.8, 11.8)	1.15 (0.85, 1.67)
No outdoor dining/bar	1384	53	633.8	8.4 (6.4, 10.7)	-ref-
Visited place of worship	341	26	158	16.4 (11.5, 21)	**1.95 (1.25, 2.93)**
Did not visit place of worship	2939	119	1404.02	8.4 (7.1, 10)	-ref-

Visited public park/public pool	2323	103	1131.22	9.1 (7.5, 10.9)	0.94 (0.66, 1.35)
Did not visit public park/pool	957	42	430.8	9.7 (7.3, 12.9)	-ref-
Mask indoor grocery shopping					
N/A (Did not go grocery shopping)	161	8	77.77	10.3 (5.3, 19)	1.17 (0.53, 2.27)
Always	2959	125	1415.05	8.8 (7.4, 10.4)	-ref-
Sometimes	128	12	54.73	21.9 (13, 21.5)	**2.49 (1.31, 4.36)**
Never	32	0	14.47	0 (0, 20.9)	0 (0, 2.37)
Mask indoor visiting non-household members					
N/A (Did no visit non-household members indoors)	666	27	688.8	3.9 (4.7, 5.6)	-ref-
Always	1047	37	358.54	10.3 (7.5, 13.9)	**2.64 (1.6, 4.37)**
Sometimes	1081	51	369	13.8 (10.7, 17.7)	**3.54 (2.22, 5.69)**
Never	438	30	145.66	20.6 (14.8, 27.8)	**5.28 (3.11, 8.9)**
Mask indoor at work					
N/A (Did not attend indoor workplace)	1595	68	1005.17	6.7 (5.3, 8.4)	-ref-
Always	1293	59	439.83	13.4 (10.5, 16.9)	**2 (1.4, 2.81)**
Sometimes	282	13	96.81	13.4 (8, 21.6)	**2 (1.06, 3.51)**
Never	61	5	20.19	24.7 (11.1, 46.5)	**3.69 (1.3, 8.46)**
Mask indoor at salon/gym					
N/A (Did not attend salon/gym)	2426	106	1290.06	8.2 (6.8, 9.8)	-ref-
Always	699	32	237.52	13.5 (9.7, 18.4)	**1.65 (1.09, 2.41)**
Sometimes	31	3	9.91	30.3 (10.8, 60.7)	3.7 (0.92, 10.26)
Never	75	4	24.51	16.3 (6.5, 35.2)	1.99 (0.62, 4.91)
Outdoor mask use					
Mask use outdoors	1501	65	716.41	9.1 (7.2, 11.4)	0.96 (0.69, 1.33)
No mask use outdoors	1779	80	845.61	9.5 (7.6, 11.6)	-ref-
Gathered outside in groups >=10					
No	1897	66	898.78	7.3 (5.8, 9.2)	-ref-
Indoors only	224	11	104.58	10.5 (6, 17.8)	1.43 (0.72, 2.64)
Outdoors only	661	35	322.47	10.9 (7.9, 14.7)	1.48 (0.97, 2.22)
Indoors and outdoors	498	33	236.19	14 (10.1, 19)	**1.9 (1.24, 2.88)**
Movement during the pandemic					
Recent use of public transit					
Avoided or did not use	2628	113	1251.33	9 (7.5, 10.7)	-ref-
Did not avoid	652	32	310.69	10.3 (7.3, 14.2)	1.14 (0.76, 1.67)
Recent Air travel (Aug-Nov)					

Yes	410	29	199.11	14.6 (10.2, 20.1)	**1.72 (1.12, 2.55)**
No	2870	116	1362.91	8.5 (7.1, 10.1)	-ref-

Table S5.

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

Table S6. Characteristics of persons with seroprevalent and seroincident SARS-CoV-2

	All seropositive persons		Observed seroconverters (seronegative in Period 1 and seropostive in Period 2)		Prevalent cases (seropositive on first antibody test)		Seroreversions (seropositive in Period 1, seronegative in Period 2)	
Total	N	%	N	%	N	%	N	%
	303	100	145	47.9	138	45.5	20.0	6.6
Symptoms and clinical outcomes								
Aware of past SARS-CoV-2 infection (footnote)	121	39.9	35	24.1	74	53.6	12.0	60.0
PCR confirmed diagnosis	89	29.4	42	29.0	41	29.7	6.0	30.0
Asymptomatic (footnote details)	83	27.4	37	25.5	39	28.3	7.0	35.0
Mild (symptomatic, but didn't seek care)	190	62.7	87	60.0	87	63.0	16.0	80.0
History of COVID like illness at baseline*	121	39.9	51	35.2	62	44.9	8.0	40.0
Ever had COVID like illness*	209	69.0	105	72.4	93	67.4	11.0	55.0
Nasal discharge, congestion or sneezing	225	74.3	107	73.8	103	74.6	15.0	75.0
Cough/Cough up phlegm	158	52.2	77	53.1	70	50.7	11.0	55.0
Cough up blood	2	0.7	1	0.7	0	0.0	1.0	5.0
Sore throat	140	46.2	71	49.0	61	44.2	8.0	40.0
Itchy eye or eye pain	114	37.6	58	40.0	48	34.8	8.0	40.0
Shortness of breath or chest pain	91	30.0	37	25.5	49	35.5	5.0	25.0
Stomachache, diarrhea, nausea or vomiting	142	46.9	64	44.1	69	50.0	9.0	45.0
Rash	25	8.3	12	8.3	10	7.3	3.0	15.0
Loss of smell	61	20.1	30	20.7	28	20.3	3.0	15.0
Headache	202	66.7	93	64.1	97	70.3	12.0	60.0
Fever, chills or repeated chills	120	39.6	50	34.5	61	44.2	9.0	45.0
Myalgia	106	35.0	58	40.0	45	32.6	3.0	15.0
Ever hospitalized	10	3.3	3	2.1	7	5.1	0.0	0.0
Public health outcomes and testing history								
Ever tested for COVID	195	64.4	92	63.5	91	65.9	12	60.0
Postive SARS-CoV-2 PCR test	97	32.0	43	29.7	48	34.8	6.0	30.0
Isolated from people outside household	93	30.7	42	29.0	45	32.6	6	30.0
Isolated from people within household	41	13.5	23	15.9	16	11.6	2	10.0
Quarantined after contact with COVID	30	9.9	23	15.9	6	4.3	1	5.0
Asked about contacts after COVID diagnosis	54	17.8	29	20.0	24	17.4	1	5.0
Told about contacts with COVID case	23	7.6	10	6.9	8	5.8	5	25.0
Encouraged to get tested because of contact with COVID case	12	4.0	6	4.1	2	1.4	4	20.0
Told to stay home for a period of time	10	3.3	4	2.8	4	2.9	2	10.0

*based on CTSE case definition

Table S6.

Characteristics of persons with seroprevalent and seroincident SARS-CoV-2

Table S7. Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein

	Specimens positive by Total Ab in Period 1 or Period 2		**Individuals positive by Total Ab in Period 1**		**Individuals positive by Total Ab in Period 2**		**Seroconverters (seropositive by Total AB in Period 1, seronegative by Total AB in Period 2)**		**Seroreverters (seropositive by Total AB in Period 1, seronegative by Total Ab in Period 2)**	
Total									N	%
	392	100%	134	100%	258	100%	145	100%	20	100.0
Spike IgG result										
Equivocal	28	7.1%	8	6.0%	20	7.8%	6	4.1%	2	10.0%
Non-Reactive	132	33.7%	31	23.1%	101	39.1%	64	44.1%	13	65.0%
Quantity Not Sufficient	31	7.9%	7	5.2%	24	9.3%	14	9.7%	0	0.0%
Reactive	201	51.3%	88	65.7%	113	43.8%	61	42.1%	5	25.0%
% reactive (excluding QNS**)		63.4%		75.6%		56.8%		51.1%		35.0%

*392 seropositive samples from 303 seropositive participants
**Quantity not sufficient for serologic testing

Table S7.

Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein